How semaglutide is linked to hair loss
The connection between semaglutide and hair shedding is real and documented, but the mechanism is indirect. Wegovy's FDA-approved prescribing information lists alopecia as an adverse reaction, appearing in 3% of adults treated with semaglutide 2.4 mg in the pooled STEP 2, 3, and 4 clinical trials, compared with 1% of adults in the placebo group. The label explicitly states that these hair loss events were "associated with weight reduction," not with any direct pharmacological effect of the drug on scalp tissue or follicle biology.
This distinction matters clinically. When people lose a significant amount of weight quickly, regardless of how that weight loss happened, the body responds by shifting hair follicles into a resting state. The drug creates the conditions for rapid weight loss; the weight loss, in turn, triggers the hair change. All clinical trial data on semaglutide and hair loss cited in this article refers to studies of Wegovy, an FDA-approved product. Compounded semaglutide is not FDA-approved and has not been evaluated in equivalent clinical trials; findings from the STEP program cannot be assumed to apply to compounded formulations.
Individual results vary. Weight loss and other outcomes depend on starting weight, medical history, adherence to treatment, and lifestyle factors. These statements have not been evaluated by the FDA.
What telogen effluvium is and why rapid weight loss triggers it
Telogen effluvium is a temporary form of diffuse hair shedding that occurs when a large number of follicles shift prematurely from the growth phase (anagen) into the resting phase (telogen) at the same time. Under normal conditions, roughly 85 to 90% of scalp follicles are in the anagen phase at any moment, while about 10% rest quietly in telogen before shedding. When the body experiences significant physical stress, such as rapid weight loss, major surgery, serious illness, or severe calorie restriction, a much larger proportion of follicles enter telogen together. Weeks later, those resting hairs all fall out in a compressed window, producing the noticeable shedding people report.
With GLP-1 medications like semaglutide, calorie intake can drop sharply because appetite suppression is a primary mechanism of the drug. Hair cells are among the fastest-dividing cells in the body and require a steady supply of protein and energy. A 2024 retrospective study of 140 patients with weight-loss-related telogen effluvium published in a peer-reviewed dermatology journal concluded that the trigger is "probably not direct weight loss but rather the restriction of caloric intake during dieting," because low calorie availability impairs the high cell-turnover rate of the hair matrix. This is not unique to semaglutide: the same phenomenon occurs after crash dieting, bariatric surgery, or any other approach that produces rapid weight reduction.
What the Wegovy clinical trials report about hair loss rates
The STEP clinical trial program provides the most reliable numbers currently available. In the STEP 1 trial, a 68-week randomized controlled study of semaglutide 2.4 mg in adults with obesity or overweight, participants lost a mean of 14.9% of body weight over the study period. Alopecia occurred at a rate of approximately 3% in the active drug group versus roughly 1% in the placebo group, a pattern consistent with the pooled adverse-event data from STEP 2, 3, and 4 in the prescribing label.
The breakdown by sex reflects what is seen broadly in telogen effluvium research: 4% of women in the Wegovy trials reported alopecia on the drug compared with 2% on placebo, while 0.9% of men reported it compared with 0% on placebo. The retrospective study of 140 telogen effluvium patients found that 78.6% were women, even though male participants in that study lost weight at a faster rate per month. Women appear to be more biologically susceptible to this particular stress response in the hair follicle cycle, though the reasons are not fully understood.
Notably, alopecia does not appear as a listed adverse reaction in the prescribing information for Ozempic, the lower-dose semaglutide formulation approved for type 2 diabetes management. At those doses, typical weight loss is more modest, which is consistent with the idea that degree of weight change, rather than semaglutide exposure itself, drives the risk.
More weight lost means higher risk
The association between the amount of weight lost and the likelihood of hair shedding is one of the clearest patterns in the available data. Among Wegovy trial participants who lost more than 20% of their body weight, 5.3% reported alopecia, compared with 2.5% of those who lost less than 20%, according to information in the Wegovy prescribing information. This dose-response relationship supports the interpretation that follicular stress scales with the magnitude of weight change.
The pattern extends across GLP-1 medications. A 2026 joint advisory from the Obesity Medicine Association, the American Society for Nutrition, the American College of Lifestyle Medicine, and the Obesity Society cited hair loss rates from clinical trial programs for both approved GLP-1 drugs. The table below summarizes those figures. These rates come from separate clinical programs with different enrolled populations and protocols; a direct head-to-head comparison has not been conducted, so cross-drug comparisons should be interpreted with caution. See semaglutide vs tirzepatide for a full breakdown of how these two medications differ.
| Medication (FDA-approved product) | Average trial weight loss | Alopecia rate (active drug) | Alopecia rate (placebo) |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) for weight management | ~15% | 3% | 1% |
| Tirzepatide (Zepbound) for weight management | ~22% | 5% | 1% |
| Semaglutide 0.5-2.0 mg (Ozempic) for type 2 diabetes | ~4-5% | Not listed in prescribing label | Not listed |
Sources: Wegovy prescribing information; OMA/ASN/ACLM/Obesity Society 2026 joint advisory. Compounded semaglutide and compounded tirzepatide are not FDA-approved and have not been evaluated in equivalent clinical trials.
When shedding starts and how long it typically lasts
The hair follicle cycle introduces a built-in delay between the triggering event and visible shedding. Follicles that enter telogen because of calorie restriction or metabolic stress do not shed immediately; they rest for several weeks before releasing the hair shaft. Most people on semaglutide who develop telogen effluvium notice increased shedding roughly 2 to 4 months after beginning treatment, corresponding to the period when calorie restriction and weight change are most pronounced.
The 2024 retrospective study of 140 patients found a mean onset of hair loss approximately 1.12 months after the weight loss period began, with a mean recovery period of 4.83 months without any specific hair treatment. The Cleveland Clinic notes that under normal circumstances people shed up to 100 hairs per day, while those with active telogen effluvium may lose around 300 per day, and that the condition resolves in approximately 95% of acute cases within six months once the underlying trigger stabilizes. For people on semaglutide, stabilization typically means the pace of weight loss has slowed as the body approaches a new equilibrium at a lower weight.
Protein intake: the most modifiable factor during treatment
Hair shafts are made almost entirely of keratin, a structural protein that requires a sustained supply of amino acids for synthesis. When calorie intake falls sharply, the body prioritizes vital organs, and hair follicle activity is among the first processes to be scaled back. Adequate protein intake does not guarantee that telogen effluvium will not occur, but insufficient protein intake makes the risk meaningfully higher.
The standard dietary protein recommendation for healthy adults is 0.8 grams per kilogram of body weight per day. The 2026 joint advisory from the Obesity Medicine Association, the American Society for Nutrition, the American College of Lifestyle Medicine, and the Obesity Society recommends that people on GLP-1 medications target 1.2 to 1.6 grams per kilogram of body weight per day during active weight reduction, distributed across three to four meals. The advisory identifies signs of nutritional insufficiency to watch for, including fatigue beyond expected levels and excessive hair loss, and notes that these can emerge at calorie intakes below 1,200 calories per day for women and 1,800 per day for men. Reaching protein targets while appetite is suppressed often requires deliberately prioritizing protein sources first at every meal and, when appetite is very low, using protein-rich beverages or supplements to close the gap.
Iron, zinc, and biotin: test before supplementing
Supplement marketing for hair loss is aggressive, but the clinical evidence for most individual nutrients is more limited and condition-specific than the marketing implies. Three nutrients, iron, zinc, and biotin, deserve direct attention because they appear frequently in discussions of GLP-1-related hair loss, and the responsible guidance for each is the same: test first, then decide.
Iron. Low serum ferritin (the stored form of iron) has been documented more frequently in people with chronic telogen effluvium and female pattern hair loss. A 2023 study on iron deficiency and alopecia found that the ferritin level adequate to support normal hair growth is approximately 40 to 60 ng/mL, notably higher than the threshold commonly used to define clinical anemia. People losing weight on semaglutide who are eating less may be at heightened risk for iron insufficiency, but a routine complete blood count will not catch it; serum ferritin is the correct test. Iron supplementation without confirmed deficiency carries real risks, including gastrointestinal effects and, at higher doses, iron overload, so supplementing without testing is not appropriate.
Zinc. Studies have documented lower serum zinc levels in people with several types of hair loss compared with healthy controls. However, excess zinc interferes with copper absorption and can impair immune function. The same principle applies: documented deficiency warrants a clinical conversation about supplementation; assumption of deficiency without testing does not.
Biotin. Biotin is produced by intestinal bacteria and dietary deficiency is uncommon in adults eating a varied diet. A comprehensive review published in the Journal of Investigative Dermatology Symposium Proceedings found that no clinical trials have demonstrated biotin supplementation to be effective for hair loss in the absence of a confirmed biotin deficiency. Taking biotin without a documented deficiency is unlikely to help and can interfere with certain thyroid and cardiac laboratory tests, producing false results. A clinician can assess whether any of these nutrients warrant testing based on dietary history and symptoms.
When hair loss signals something other than telogen effluvium
Telogen effluvium has a characteristic appearance that distinguishes it from other causes of hair loss worth knowing about. The shedding is diffuse, meaning it occurs evenly across the whole scalp. Someone may notice more hair on the pillow, in the shower drain, or on a brush, and overall scalp coverage may appear thinner, but there are no completely bare patches and the hairline remains intact. The scalp itself is normal in appearance: no redness, no scaling, no itching, and no burning sensations.
Two patterns should prompt a visit to a dermatologist rather than watchful waiting. First, patchy hair loss with clearly defined round or oval bald spots appearing suddenly anywhere on the scalp or eyebrows is the classic presentation of alopecia areata, an autoimmune condition that is unrelated to weight loss and requires its own evaluation and treatment. A 2025 scoping review of GLP-1 medications and alopecia published in a peer-reviewed medical journal identified rare cases of frontal fibrosing alopecia and discoid lupus erythematosus among GLP-1 users, conditions involving immune activity that are distinct from telogen effluvium.
Second, scalp symptoms including itching, flaking, redness, tenderness, or a burning sensation alongside hair loss suggest conditions such as seborrheic dermatitis, tinea capitis (scalp ringworm), or lichen planopilaris, none of which are related to semaglutide or weight loss. Any hair loss accompanied by scalp symptoms, any patchy or circular bald spots, or any shedding that continues beyond six months without signs of slowdown warrants a clinical evaluation. A dermatologist or trichologist can perform a physical exam and, if needed, a pull test or scalp biopsy to identify the cause.
What to expect during and after the shedding phase
For the majority of people who develop telogen effluvium during semaglutide treatment, regrowth follows naturally as weight loss pace slows. Hair grows approximately half an inch (about 1.25 cm) per month, so even after shedding stops and new hairs emerge from the follicle, it takes several additional months for those hairs to grow long enough to visibly fill in thinner areas. Most people report a noticeable improvement in hair density within 6 to 12 months of the shedding period ending.
There is currently no evidence from peer-reviewed research that semaglutide-associated hair loss permanently damages hair follicles. The 2025 review published in a peer-reviewed medical journal on semaglutide and alopecia confirms that the predominant mechanism is telogen effluvium, in which follicles remain intact and viable throughout the episode, meaning regrowth capacity is preserved. Practical steps that support the recovery period include maintaining adequate protein intake across meals, correcting any documented nutritional deficiencies with clinician guidance, and avoiding additional stressors such as very restrictive crash dieting or harsh chemical hair treatments. A dermatologist can also assess whether topical treatments such as minoxidil are appropriate for an individual case during the regrowth phase.
Prescription required. Compounded semaglutide is available only after evaluation and approval by a licensed healthcare provider. Not all patients are eligible.